Sernova Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Sernova's net margins, return on equity and return on assets.

Institutional and Insider Ownership

52.5% of Ocular Therapeutix shares are owned by institutional investors. 7.7% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Ocular Therapeutix and Sernova's gross revenue, earnings per share (EPS) and valuation.

Sernova has lower revenue, but higher earnings than Ocular Therapeutix.

Analyst Recommendations

This is a summary of current ratings and price targets for Ocular Therapeutix and Sernova, as provided by MarketBeat.

Ocular Therapeutix presently has a consensus target price of $24.80, indicating a potential upside of 67.79%. Given Ocular Therapeutix's higher probable upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Sernova.

Summary

Ocular Therapeutix beats Sernova on 9 of the 12 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMO) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Profitability

This table compares Avid Bioservices and Sernova's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Avid Bioservices and Sernova's gross revenue, earnings per share and valuation.

Sernova has lower revenue, but higher earnings than Avid Bioservices.

Institutional & Insider Ownership

58.2% of Avid Bioservices shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Avid Bioservices and Sernova, as provided by MarketBeat.com.

Avid Bioservices presently has a consensus target price of $17.3333, indicating a potential downside of 8.82%. Given Avid Bioservices' higher probable upside, analysts clearly believe Avid Bioservices is more favorable than Sernova.

Volatility & Risk

Avid Bioservices has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Summary

Avid Bioservices beats Sernova on 9 of the 11 factors compared between the two stocks.

Sernova (OTCMKTS:SEOVF) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Sernova and Protagonist Therapeutics, as provided by MarketBeat.

Protagonist Therapeutics has a consensus target price of $38.00, indicating a potential upside of 42.75%. Given Protagonist Therapeutics' higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Sernova.

Institutional and Insider Ownership

97.5% of Protagonist Therapeutics shares are held by institutional investors. 14.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Sernova has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sernova and Protagonist Therapeutics' revenue, earnings per share and valuation.

Sernova has higher earnings, but lower revenue than Protagonist Therapeutics.

Profitability

This table compares Sernova and Protagonist Therapeutics' net margins, return on equity and return on assets.

Summary

Protagonist Therapeutics beats Sernova on 9 of the 11 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Sernova's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Y-mAbs Therapeutics and Sernova, as reported by MarketBeat.com.

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, indicating a potential upside of 122.68%. Given Y-mAbs Therapeutics' higher probable upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than Sernova.

Risk & Volatility

Y-mAbs Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Y-mAbs Therapeutics and Sernova's net margins, return on equity and return on assets.

Summary

Y-mAbs Therapeutics beats Sernova on 7 of the 9 factors compared between the two stocks.

Sernova (OTCMKTS:SEOVF) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares Sernova and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sernova and Phathom Pharmaceuticals' top-line revenue, earnings per share and valuation.

Volatility and Risk

Sernova has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sernova and Phathom Pharmaceuticals, as provided by MarketBeat.com.

Phathom Pharmaceuticals has a consensus target price of $53.00, indicating a potential upside of 49.72%. Given Phathom Pharmaceuticals' higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Sernova.

Summary

Phathom Pharmaceuticals beats Sernova on 7 of the 9 factors compared between the two stocks.

Kronos Bio (NASDAQ:KRON) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Kronos Bio and Sernova's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Kronos Bio and Sernova's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Kronos Bio and Sernova, as reported by MarketBeat.

Kronos Bio currently has a consensus price target of $43.6667, indicating a potential upside of 117.46%. Given Kronos Bio's higher possible upside, equities analysts clearly believe Kronos Bio is more favorable than Sernova.

Summary

Kronos Bio beats Sernova on 4 of the 4 factors compared between the two stocks.